These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 32729746)

  • 1. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins.
    Hirota T; Fujita Y; Ieiri I
    Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):809-822. PubMed ID: 32729746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
    Neuvonen PJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-drug interactions that interfere with statin metabolism.
    Hirota T; Ieiri I
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1435-47. PubMed ID: 26058399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
    Neuvonen PJ; Backman JT; Niemi M
    Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
    Shitara Y; Sugiyama Y
    Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
    Cooper-DeHoff RM; Niemi M; Ramsey LB; Luzum JA; Tarkiainen EK; Straka RJ; Gong L; Tuteja S; Wilke RA; Wadelius M; Larson EA; Roden DM; Klein TE; Yee SW; Krauss RM; Turner RM; Palaniappan L; Gaedigk A; Giacomini KM; Caudle KE; Voora D
    Clin Pharmacol Ther; 2022 May; 111(5):1007-1021. PubMed ID: 35152405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.
    Chauvin B; Drouot S; Barrail-Tran A; Taburet AM
    Clin Pharmacokinet; 2013 Oct; 52(10):815-31. PubMed ID: 23703578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
    Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological interactions of statins.
    Paoletti R; Corsini A; Bellosta S
    Atheroscler Suppl; 2002 May; 3(1):35-40. PubMed ID: 12044584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical response to statins: mechanism(s) of variable activity and adverse effects.
    Sirtori CR; Mombelli G; Triolo M; Laaksonen R
    Ann Med; 2012 Aug; 44(5):419-32. PubMed ID: 21623698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.
    Zhou YT; Yu LS; Zeng S; Huang YW; Xu HM; Zhou Q
    Ther Clin Risk Manag; 2014; 10():17-26. PubMed ID: 24379677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of pharmacogenetic variation on the effects of statins.
    Maggo SD; Kennedy MA; Clark DW
    Drug Saf; 2011 Jan; 34(1):1-19. PubMed ID: 21142270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.
    Hu M; Tomlinson B
    Expert Opin Drug Metab Toxicol; 2014 Jan; 10(1):51-65. PubMed ID: 24156555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin safety and drug interactions: clinical implications.
    Bottorff MB
    Am J Cardiol; 2006 Apr; 97(8A):27C-31C. PubMed ID: 16581325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction potential between clarithromycin and individual statins-A systematic review.
    Hougaard Christensen MM; Bruun Haastrup M; Øhlenschlaeger T; Esbech P; Arnspang Pedersen S; Bach Dunvald AC; Bjerregaard Stage T; Pilsgaard Henriksen D; Thestrup Pedersen AJ
    Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):307-317. PubMed ID: 31628882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.
    Schachter M
    Fundam Clin Pharmacol; 2005 Feb; 19(1):117-25. PubMed ID: 15660968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
    Igel M; Sudhop T; von Bergmann K
    Eur J Clin Pharmacol; 2001 Aug; 57(5):357-64. PubMed ID: 11599653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
    Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
    Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.